ArticleJournal of neuro-oncology2021
Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients.
Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- A Radiomics-Driven Model to Distinguish Between Clinically Similar Myxopapillary Ependymomas and Lumbosacral Schwannomas.Neurosurgery practice · 2026Article
- Clinical and Magnetic Resonance Features of Spinal Myxopapillary Ependymoma.Neurosurgery practice · 2026Article
- Single-nucleus transcriptomics of spinal ependymoma subtypes recognizes intratumoral heterogeneity.Neuro-oncology · 2026Article
- Primary intracranial myxopapillary ependymoma: two case reports and literature review.Frontiers in oncology · 2026Article
- Radiological analysis correlated with neurological outcomes following resection of myxopapillary ependymoma: patient series.Journal of neurosurgery. Case lessons · 2025Article
- Bilateral Papilledema in a Child with Spinal Myxopapillary Ependymoma: A Case Report.The American journal of case reports · 2025Article
- Specifics of spinal neuropathology in the molecular age.Neuro-oncology advances · 2024Review
- Outcomes and Pattern of Care for Spinal Myxopapillary Ependymoma in the Modern Era-A Population-Based Observational Study.Cancers · 2024Article
- Development of a novel prediction model for differential diagnosis between spinal myxopapillary ependymoma and schwannoma.Scientific reports · 2024Article
- Review
- Clinical management and prognosis of spinal myxopapillary ependymoma: a single-institution cohort of 72 patients.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2023Article
- Myxopapillary Ependymoma-a Case Report of Rare Multicentric Subtype and Literature Review.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2023Review
- Spinal ependymoma in adults: from molecular advances to new treatment perspectives.Frontiers in oncology · 2023Review
- Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.Neuro-oncology · 2022Article
- Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022Review
- Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.Brain pathology (Zurich, Switzerland) · 2022Review
- Myxopapillary ependymomas; proximity to the conus and its effect on presentation and outcomes.Surgical neurology international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMyxopapillary ependymoma (MPE) is the most frequent tumor affecting the medullary conus. The surgical therapeutic management is still debated and only few studies have focused on the postoperative clinical outcome of patients. This study aimed to demonstrate long-term postoperative outcome and to assess the predictive factors of recurrence as well as the clinical evolution of these patients.
methodsFrom 1984 to 2019, in four French centers, 101 adult patients diagnosed with MPE were retrospectively included.
resultsMedian age at surgery was 39 years. Median tumor size was 50 mm and lesions were multifocal in 13% of patients. All patients benefited from surgery and one patient received postoperative radiotherapy. Gross total resection was obtained in 75% of cases. Sixteen percent of patients presented recurrence after a median follow-up of 70 months. Progression free survival at 5 and 10 years were respectively estimated at 83% and 79%. After multivariable analysis, sacral localization, and subtotal resection were shown to be independently associated with tumor recurrence. 85% of the patients had a favorable evolution concerning pain. 12% of the patients presented a postoperative deterioration of sphincter function and 4% of motor function.
conclusionSurgery alone is an acceptable option for MPE patients. Patients with sacral location or incomplete resection are at high risk of recurrence and should be carefully monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.